AEterna Zentaris to Present at Upcoming Bio CEO and Wells Fargo Conferences in New York City
February 14 2005 - 10:26AM
PR Newswire (US)
AEterna Zentaris to Present at Upcoming Bio CEO and Wells Fargo
Conferences in New York City QUEBEC CITY, Feb. 14
/PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; Nasdaq:
AEZS) today announced that Gilles Gagnon, President and Chief
Executive Officer of the Company, will present a corporate update
at the Bio CEO & Investor Conference 2005 on Wednesday,
February 23, 2005, at 2:00 p.m. ET, in the Basildon room of the
Waldorf-Astoria Hotel in New York City. Furthermore, on Tuesday,
March 1, 2005, at 9:00 a.m. ET, Mr. Gagnon will present a corporate
update at the Wells Fargo Conference in the Fontainebleau room of
the St. Regis Hotel in New York City. A live webcast of both these
presentations will be available on AEterna Zentaris' website in the
Investors section at http://www.aeternazentaris.com/ About AEterna
Zentaris Inc. AEterna Zentaris Inc. is an oncology and endocrine
therapy focused biopharmaceutical company with proven expertise in
drug discovery, development and commercialization. The Company's
broad 20 product pipeline leverages five different therapeutic
approaches, including LHRH antagonists and signal transduction
inhibitors. The lead LHRH antagonist compound, cetrorelix, is
currently marketed for in vitro fertilization under the brand name
Cetrotide(R), and has successfully completed a broad Phase II
program in endometriosis and benign prostatic hyperplasia (BPH).
The lead signal transduction inhibitor compound, perifosine, is an
orally-active AKT inhibitor that is in several Phase II trials for
multiple cancers. AEterna Zentaris also owns 61.1% of Atrium
Biotechnologies Inc., an international company that develops,
manufactures and markets added-value products for the cosmetics,
pharmaceutical, chemical and nutritional industries. News releases
and additional information about AEterna Zentaris are available on
its Web site http://www.aeternazentaris.com/ . Forward-Looking
Statements This press release contains forward-looking statements
made pursuant to the safe harbor provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the ability of the Company to take advantage of business
opportunities in the pharmaceutical industry, uncertainties related
to the regulatory process and general changes in economic
conditions. Investors should consult the Company's quarterly and
annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned not to rely
on these forward-looking statements. The Company does not undertake
to update these forward-looking statements. DATASOURCE: AETERNA
ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA
CONTACT: Media Relations, Paul Burroughs, (418) 652-8525 ext. 406,
; Investor Relations, Ginette Vallieres, (418) 652-8525, ext. 265,
; Europe Matthias Seeber +49-6942602-3425 ; To request a free copy
of this organization's annual report, please go to
http://www.newswire.ca/ and click on reports@cnw.
Copyright